GoodRx Holdings, Inc. (GDRX) SEC Filings & Earnings Calls

Insider selling / distribution

“the remaining 2,743,043 Class A Shares received upon such conversion were sold by the FP Entities for an aggregate consideration of $9,678,731.4997” · word for word

Insider selling / distribution

“the remaining 2,743,043 Class A Shares received upon such conversion were sold by the FP Entities for an aggregate consideration of $9,678,731.4997” · word for word

Prescription transactions revenue declining due to retail pharmacy changes and shift to subscriptions.

“Prescription transactions revenue decreased 26% due to store closures and volume reduction.”

Government platform disruption

“The potential impact of TrumpRx on our business, offerings, or results of operations remains uncertain and could be material.” · word for word

Retail pharmacy consolidation

“Rite Aid announced its plan to pursue a sale of substantially all of its assets through a voluntary bankruptcy process... we saw several PBMs remove Rite Aid from their networks, causing immediate cessation in the associated claims volume.” · word for word

PBM network renegotiation

“We have seen and continue to expect heightened renegotiations between pharmacies and PBMs, including changes in retailer reimbursement models.” · word for word

CFO transition may cause short-term uncertainty.

“CFO departure and appointment of new CFO.”

Revenue decline from pharmacy closures and PBM changes

“These external factors have adversely impacted our prescription transactions revenue, financial results, and Monthly Active Consumers that we expect will continue in the near term” · word for word

Uncertain impact from TrumpRx

“The potential impact of TrumpRx on our business, offerings, or results of operations remains uncertain and could be material.” · word for word

Near-term margin pressure from investment in new offerings

“As we increase investment in our Pharma Direct as well as subscription offerings, we expect near-term impact on our prescription transactions unit economics and revenue in 2026.” · word for word

Prescription transactions revenue decline due to retail pharmacy store closures and volume reduction in integrated savings programs; expected to continue near-term.

“Prescription transactions revenue decreased 24%... driven by a decrease in the number of our Monthly Active Consumers due to the broader changes in the retail pharmacy landscape including store closures, volume reduction in one of our integrated savings programs, as well as lower unit economics which we expect to continue in the near-term.” · word for word

Net income margin compressed to 0.6% from 5.4% YoY, indicating earnings pressure despite revenue guidance raise.

“Net income margin was 0.6% compared to 5.4%.” · word for word

Revenue concentration and growth risk

“Revenue $796.9M missed threshold of $810M for bonus payout”

Key person retention risk

“CEO and CFO received $2M and $1M retention bonuses respectively, indicating retention concerns.”

Controlled company governance risk

“Sponsor Stockholders control >50% voting power; Compensation and Nominating committees not fully independent.”

PBM Dependency and Network Risk

“in 2025, we saw a material volume reduction in one of our integrated savings programs, which integrate our competitive discounts and pricing in a seamless experience at the pharmacy counter for eligible plan members served by certain PBM partners.” · word for word

Pharmacy Closure Impact

“we saw several PBMs remove Rite Aid from their networks, causing immediate cessation in the associated claims volume, as well as rapid store closures, which altogether adversely impacted our ability to recapture these claims in the near term.” · word for word

Government Policy Uncertainty

“Any potential impact on our business, offerings, or results of operations are unclear at this time but may be significant.” · word for word

Revenue decline guidance for FY2026 due to retail pharmacy landscape changes and subscription declines.

“FY2026 revenue guided $750-780M, down 2-6% YoY.”

High debt load of $495M relative to cash of $261.8M.

“Total outstanding debt of $495.0 million.” · word for word

Prescription transactions revenue decline due to retail pharmacy store closures and volume reduction in integrated savings programs.

“Prescription transactions revenue decreased 9%... driven by a decrease in the number of our Monthly Active Consumers, due to the broader changes in the retail pharmacy landscape, including store closures.” · word for word

Q4 revenue expected to decline sequentially due to timing of certain manufacturer deals.

“We expect fourth quarter revenue to decline sequentially due to the timing of certain manufacturer deals that closed earlier than anticipated.” · word for word

Retail Pharmacy Disruption

“Prescription transactions revenue decreased $13.1 million, or 9%, year-over-year, primarily driven by a decrease in the number of our Monthly Active Consumers...due to the broader changes in the retail pharmacy landscape including store closures and volume reduction in one of our integrated savings programs.” · word for word

Regulatory and Policy Risk

“In July 2025, Congress passed a budget bill that cuts federal funding for Medicaid among other health insurance programs, as well as tightens eligibility requirements and increases the frequency of Medicaid coverage determinations.” · word for word

Litigation Risk

“General and administrative expenses increased $6.4 million, or 25%, year-over-year, primarily driven by a $5.5 million estimated probable loss with respect to an ongoing class action litigation recognized in the third quarter of 2025.” · word for word